Jerome Charles Bressi - 15 Jan 2025 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
Chief Regulatory and Quality Officer
Signature
/s/ Cindy Tahl, as Attorney-in-Fact
Issuer symbol
FATE
Transactions as of
15 Jan 2025
Net transactions value
$0
Form type
4
Filing time
16 Jan 2025, 18:31:40 UTC
Previous filing
13 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Award $0 +65,000 +24% $0.000000 335,203 15 Jan 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Award $0 +250,000 $0.000000 250,000 15 Jan 2025 Common Stock 250,000 $1.32 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of January 8, 2026, January 8, 2027, January 8, 2028 and January 8, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.
F2 The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2025, such that all of the shares shall be fully vested and exercisable on January 1, 2028, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.

Remarks:

Chief Regulatory and Quality Officer